Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
Authors:
- Mojtaba AkhtariMAMojtaba Akhtari
- Edmund K. WallerEWEdmund K. Waller
- David L. JayeDJDavid L. Jaye
- David H. LawsonDLDavid H. Lawson
- Ramy IbrahimRIRamy Ibrahim
- Nicholas E. PapadopoulosNPNicholas E. Papadopoulos
- Martha L. ArellanoMAMartha L. Arellano
- 1 April 2009
- journal article
- case report
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 32 (3) , 322-324
Abstract
A 42-year-old white woman with a diagnosis of metastatic melanoma developed severe neutropenia during treatment with ipilimumab (anticytotoxic T-lymphocyte-associated antigen-4 antibody). Bone marrow aspiration and biopsy specimens revealed marked myeloid hypoplasia, with unremarkable erythropoiesis and megakaryopoiesis. The patient's neutropenia did not respond to therapy with a combination of colony stimulating factors and steroids; however, it rapidly improved after administration of intravenous immunoglobulin. Treatment with ipilimumab has not been reported to be associated with hematologic toxicities, and to our knowledge, no case of neutropenia has previously been reported. This report of acute grade 4 neutropenia associated with ipilimumab and clinically consistent with an autoimmune process emphasizes the importance of monitoring complete blood count during treatment with this new monoclonal antibody.Keywords
This publication has 18 references indexed in Scilit:
- Idiosyncratic drug-induced agranulocytosis or acute neutropeniaCurrent Opinion in Hematology, 2008
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006
- Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal CancerJournal of Immunotherapy, 2005
- Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4Journal of Clinical Oncology, 2005
- Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanomaJournal of Clinical Oncology, 2005
- Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV MelanomaJournal of Clinical Oncology, 2005
- Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus MacaquesThe Journal of Immunology, 2003
- Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsProceedings of the National Academy of Sciences, 2003
- CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor ImmunotherapyAnnual Review of Immunology, 2001
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity, 1995